Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients.
Yamasaki K, Tateyama M, Abiru S, Komori A, Nagaoka S, Saeki A, Hashimoto S, Sasaki R, Bekki S, Kugiyama Y, Miyazoe Y, Kuno A, Korenaga M, Togayachi A, Ocho M, Mizokami M, Narimatsu H, Yatsuhashi H. Yamasaki K, et al. Among authors: tateyama m. Hepatology. 2014 Nov;60(5):1563-70. doi: 10.1002/hep.27305. Epub 2014 Oct 2. Hepatology. 2014. PMID: 25042054 Free PMC article.
[A case of ectopic hepatocellular carcinoma].
Fukuda S, Yano K, Ohata K, Nonaka K, Tateyama M, Taura N, Komori A, Abiru S, Yatsuhashi H, Ito M, Fujioka H, Ishibashi H. Fukuda S, et al. Among authors: tateyama m. Nihon Shokakibyo Gakkai Zasshi. 2009 Dec;106(12):1770-7. Nihon Shokakibyo Gakkai Zasshi. 2009. PMID: 19966520 Review. Japanese.
Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus.
Tateyama M, Yatsuhashi H, Taura N, Motoyoshi Y, Nagaoka S, Yanagi K, Abiru S, Yano K, Komori A, Migita K, Nakamura M, Nagahama H, Sasaki Y, Miyakawa Y, Ishibashi H. Tateyama M, et al. J Gastroenterol. 2011 Jan;46(1):92-100. doi: 10.1007/s00535-010-0293-6. Epub 2010 Aug 14. J Gastroenterol. 2011. PMID: 20711614
Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma.
Narahara S, Watanabe T, Nagaoka K, Fujimoto N, Furuta Y, Tanaka K, Tokunaga T, Kawasaki T, Yoshimaru Y, Setoyama H, Oniki K, Saruwatari J, Tateyama M, Naoe H, Tanaka M, Tanaka Y, Sasaki Y. Narahara S, et al. Among authors: tateyama m. Hepatol Commun. 2022 May;6(5):1198-1212. doi: 10.1002/hep4.1872. Epub 2021 Nov 27. Hepatol Commun. 2022. PMID: 34837478 Free PMC article.
A genome-wide association study identifying SVEP1 variant as a predictor of response to tolvaptan for cirrhotic ascites.
Kawaratani H, Sawai H, Onishi M, Kogiso T, Shimada N, Uojima H, Nakajima T, Matsumoto N, Ikejima K, Ishikawa T, Terai S, Motoyama H, Komori A, Hirashima N, Saito S, Eguchi Y, Nojima M, Kawai Y, Tateyama M, Yoshiji H, Tanaka Y. Kawaratani H, et al. Among authors: tateyama m. Liver Int. 2021 Dec;41(12):2944-2953. doi: 10.1111/liv.15022. Epub 2021 Aug 8. Liver Int. 2021. PMID: 34309184
Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B.
Nagura Y, Matsuura K, Iio E, Fujita K, Inoue T, Matsumoto A, Tanaka E, Nishiguchi S, Kang JH, Matsui T, Enomoto M, Ikeda H, Watanabe T, Okuse C, Tsuge M, Atsukawa M, Tateyama M, Kataoka H, Tanaka Y. Nagura Y, et al. Among authors: tateyama m. PLoS One. 2022 Feb 14;17(2):e0263844. doi: 10.1371/journal.pone.0263844. eCollection 2022. PLoS One. 2022. PMID: 35157730 Free PMC article.
Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study.
Atsukawa M, Tsubota A, Kondo C, Koyano KS, Ishikawa T, Toyoda H, Takaguchi K, Watanabe T, Matsuura K, Ogawa C, Hiraoka A, Okubo H, Tateyama M, Uojima H, Nozaki A, Chuma M, Kato K, Mikami S, Tani J, Morishita A, Kawata K, Tada T, Furuichi Y, Okubo T, Kawano T, Arai T, Kawabe N, Kawamura N, Ikegami T, Nakamuta M, Shigefuku R, Iwasa M, Tanaka Y, Hatano M, Iwakiri K. Atsukawa M, et al. Among authors: tateyama m. Hepatol Int. 2023 Feb;17(1):139-149. doi: 10.1007/s12072-022-10456-y. Epub 2022 Dec 7. Hepatol Int. 2023. PMID: 36477691 Clinical Trial.
Modified albumin-bilirubin grade to predict eligibility for second-line therapies at progression on sorafenib therapy in hepatocellular carcinoma patients.
Tokunaga T, Tanaka M, Tanaka K, Narahara S, Kawasaki T, Yoshimaru Y, Nagaoka K, Watanabe T, Tateyama M, Naoe H, Sasaki Y, Tanaka Y. Tokunaga T, et al. Among authors: tateyama m. Int J Clin Oncol. 2021 May;26(5):922-932. doi: 10.1007/s10147-020-01835-2. Epub 2021 Mar 17. Int J Clin Oncol. 2021. PMID: 33730200
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.
Tokunaga T, Tateyama M, Kondo Y, Miuma S, Miyase S, Tanaka K, Narahara S, Inada H, Kurano S, Yoshimaru Y, Nagaoka K, Watanabe T, Setoyama H, Fukubayashi K, Tanaka M, Tanaka Y. Tokunaga T, et al. Among authors: tateyama m. Cancers (Basel). 2023 Mar 2;15(5):1568. doi: 10.3390/cancers15051568. Cancers (Basel). 2023. PMID: 36900359 Free PMC article.
Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity.
Tokunaga T, Tateyama M, Tanaka K, Narahara S, Inada H, Kurano S, Hayashi S, Yoshimaru Y, Nagaoka K, Watanabe T, Setoyama H, Tanaka M, Tanaka Y. Tokunaga T, et al. Among authors: tateyama m. Hepatol Res. 2022 Jan;52(1):105-119. doi: 10.1111/hepr.13720. Epub 2021 Oct 22. Hepatol Res. 2022. PMID: 34626450
406 results